Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BEAMing up personalized medicine: mutation detection in blood.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jun 2012

Richardson Andrea L, Iglehart J Dirk

Abstract excerpt

BEAMing is a feasible, accurate, and sensitive method for detection of PIK3CA mutations in circulating tumor DNA in blood. Mutation status of PIK3CA may change between primary tumor and recurrence. The results suggest a new approach for noninvasive determination of current mutation status in pati...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Class I Phosphatidylinositol 3-Kinases
Share to DNA, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutant Proteins

Share to Neoplasm Metastasis

Share to Phosphatidylinositol 3-Kinases

Share to Precision Medicine

Share to Sensitivity and Specificity

Source

Open in PubMed Open full text

Identifiers

PMID: 22550168
DOI: 10.1158/1078-0432.CCR-12-0871
PMCID: PMC3377838

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22550168-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

BEAMing up personalized medicine: mutation detection in blood.PMID 22550168Read ↗

Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood.Semantic proximity Read ↗

Comparative analysis of EGFR mutations in circulating tumor DNA and primary tumor tissues from lung cancer patients using BEAMing PCR.Semantic proximity Read ↗

LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology.Semantic proximity Read ↗

Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas.Semantic proximity Read ↗

BEAMing sheds light on drug resistance.Semantic proximity Read ↗

Comparative analysis of EGFR mutations between circulating tumor DNA and tissue samples in non-small cell lung carcinoma patients using BEAMing PCR: results of a single institutional observational studySemantic proximity Read ↗

Precision Medicine for Breast Cancer Utilizing Circulating Tumor DNA: It Is in the Blood.Semantic proximity Read ↗

Identification of E545k mutation in plasma from a PIK3CA wild-type metastatic breast cancer patient by array-based digital polymerase chain reaction: Circulating-free DNA a powerful tool for biomarker testing in advance disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.